43 Million Americans Drink Water No Federal Law Requires Anyone to Test Routinely, and 4.8 Million Untested Households May Be Above a Health Benchmark
More than 43 million Americans drink from private wells the Safe Drinking Water Act does not cover, and a home sale is the only moment testing reliably happens.
- 43 million Americans drink from private wells. No federal law requires routine testing of one, and about 4.8 million untested households may be above a health benchmark.
- PFAS is detectable in nearly half of all tap water (detection is not exceedance of the 4 ppt limit).
- The sale is the moment testing happens: about 690,000 well homes sell a year, and four states plus FHA and VA loans already compel a test in defined circumstances.
Forward this to anyone on a well: test bacteria and nitrate every year, arsenic and PFAS at least once. A full panel from a certified lab runs about $209.
The Problem
Turn on a tap in an American city and the water arrives with a paper trail: a public utility tests it on a fixed schedule, reports the results every year, and faces federal enforcement when a contaminant crosses a limit. Turn on a tap in a house with a private well and none of that exists. Around 15 percent of the US population, more than 43 million people in over 23 million households, drinks from a private well, and the EPA states plainly that the quality and safety of that water is not regulated by the federal government under the Safe Drinking Water Act, nor by most state governments. Private well owners are responsible for delivering safe drinking water to their own households, whether they know that or not.
Most have no idea. A 2022 Iowa Rural Drinking Water Survey of some 8,000 households, with Gabriel Lade, a primary researcher for CARD, among its authors, found that just 10 percent of well owners had tested their water quality in the last year. The same survey found 73 percent at risk of exposure to potentially unsafe water from a lack of recent testing or mitigation, with a third at high risk of nitrate exposure specifically. Testing was free in Iowa through a county grant program, and still only one in ten tested.
Meanwhile the water itself is not clean by default. A US Geological Survey study of about 2,100 domestic wells across 48 states found that nearly one in four wells, 23 percent, contained one or more contaminants above a human-health benchmark, with arsenic, manganese, nitrate, and strontium the most frequent inorganic chemical offenders, most of them naturally occurring in rock. Microbial contamination showed up in about a third of the roughly 400 wells tested for bacteria. The water can fail on biology as well as chemistry. A separate USGS study estimated that about 2.1 million people, with a 95 percent confidence interval of 1.5 to 2.9 million (Ayotte et al. 2017), drink well water with arsenic above the 10 microgram-per-liter federal standard, a tasteless, odorless toxin that shows up, if at all, as a health problem years later.
Then came PFAS. In 2023 the USGS published the first nationwide comparison of forever chemicals in private-well and public-supply tap water. Researchers tested 716 kitchen taps, 269 of them private wells, for dozens of PFAS compounds. It estimated that at least one PFAS could be detected in about 45 percent of US drinking-water samples, with private-well concentrations similar to public supply. In April 2024 the EPA finalized enforceable limits for six PFAS compounds in public drinking water, 4 parts per trillion for PFOA and PFOS, with compliance due April 2029, and in May 2026 the EPA proposed keeping the 4 ppt limits while allowing eligible systems to seek an exemption extending PFOA/PFOS compliance to 2031, and rescinding the other four; as of October 2026 both are still proposals and the 2024 rule stands. Private wells were exempt from the rule entirely: a well owner with the same 4 parts per trillion in the glass gets no notice, no deadline, and no treatment requirement.
City water gets tested on a schedule by law. Well water gets tested when the owner remembers, which is almost never.
What makes this a business rather than a warning is that the testing itself is solved: certified labs run EPA methods 533 and 537.1 for PFAS at parts-per-trillion sensitivity. A test result arrives as a PDF in an inbox and dies there, unread, unfiled, uncompared to anything, and useless the next time anyone asks whether the water is safe.
The 4.8-Million-Household Math Nobody Runs
Combine the published numbers, all of which sit in public EPA and USGS reports, and the scale of the blind spot becomes clear: 43 million people, more than live in California, in over 23 million households on private wells, drinking water no agency watches.
| Step | Input | Source | Result |
|---|---|---|---|
| Households on private wells | 23 million | EPA | 23,000,000 |
| Tested in the past year (Iowa, 2022) | 10% | Iowa Rural Drinking Water Survey | ~2,300,000 |
| Did not test in the past year | 90% | Calculated | ~20,700,000 |
| Share of wells above a health benchmark | 23% | USGS Circular 1332 | 23% |
| Untested households plausibly above a benchmark | 20.7M x 23% | Calculated | ~4,800,000 |
The number to remember is 4.8 million: households plausibly drinking water above a health benchmark with no test in the past year.
Applied to wells, that 45 percent implies roughly 19 million people on wells, about the population of New York State, have detectable PFAS in their drinking water, an extrapolation that could be several million in either direction.
Three assumptions carry it. The 10 percent testing rate comes from one state in one year, and the USGS 23 percent figure comes from samples collected between 1991 and 2004, before PFAS was measured in the study, so it understates current exceedances if anything, and the calculation assumes untested wells are no more or less contaminated than tested ones.
Now the transaction math. Existing-home sales totaled 4.06 million in 2024, according to the National Association of Realtors, the weakest year since 1995. About 17 percent of households in the conterminous United States had self-supplied water sources in 2020, according to the USGS, which puts roughly 690,000 well homes changing hands every year. That is the wedge: the only moment in a well's life when testing is not optional in practice, because someone else is paying, someone else set the deadline, and the loan depends on the result.
The Gap in the Market
Mail-in lab testing is a real product: the global water testing kit market was $1.8 billion in 2024, projected to reach $3.1 billion by 2034, though that covers kits worldwide including strips, pool, and marine testing, a different market from US lab panels. But every incumbent sells a single test. Not a system. A homeowner orders a kit, mails a sample, gets a result, and the relationship ends until the next time they remember, which the Iowa data says is usually never.
| Company | What They Do | What's Missing |
|---|---|---|
| Tap Score / SimpleLab | Mail-in certified lab testing with plain-English reports. Essential Well kit $209 (49 analytes plus bacteria); PFAS panel $335 for 18 compounds by EPA Method 537.1, $599 for 25 by Method 533. October 2026 comparison-site prices. | PFAS costs extra. No year-by-year record, reminders, transaction workflow, or treatment marketplace. |
| National Testing Laboratories (WaterCheck) | ISO/IEC 17025-accredited lab operating since 1985. City and well kits $169 to $345, up to 115 analytes. October 2026 comparison-site prices. | Results arrive as a report, not a dashboard. PFAS needs a second order elsewhere. No subscription, reminders, or persistent record. |
| Cyclopure | NIEHS-funded PFAS test kit at around $85 covering 55 PFAS compounds. | PFAS only: no bacteria, metals, nitrate, or radiologicals. No ongoing monitoring. |
| Local certified labs and county health departments | The default channel for most well owners: drop off a bottle, get a result in a week or two. | Fragmented by county, no online ordering, interpretation, trend tracking, or lending integration. DIY strips at $10 to $30 cannot detect PFAS at any level or arsenic at health-relevant levels; they give only presence/absence for bacteria and flag lead only at high levels. |
| Culligan and local treatment dealers | Sell and install filtration and softening systems, often with a free basic test as the sales hook. | The test exists to sell the system. Advice is not independent, results are not portable, and nothing verifies the fix worked. |
Across every player the pattern is the same: testing is sold as a one-time event, and results arrive as a static document, and the two moments testing actually happens, a home sale and a scare, are served by whoever happens to be nearby. Nobody owns the record of a well over time, or the handoff from a failing result to a verified fix. That is the opening.
The same chemical at the same concentration is a federal violation in a city and a private matter on a farm.
The Solution
A testing and compliance platform for private wells has five parts. The product is not the lab test. Never was. The product is the record, the reminder, and the verified fix.
1. Annual testing subscription
The core recurring product costs $149 a year, which includes the annual kit and lab work. The $209 Tap Score panel is the ร -la-carte price for a one-off test, not an add-on. Each year the subscriber receives a kit timed to their well's risk profile. Results land in a dashboard that benchmarks each contaminant against EPA limits, shows the trend across years, and flags changes, not just exceedances. A nitrate level that doubled since last year matters even if it is still under the limit. Reminders go out automatically, because the entire failure mode is forgetting.
2. Transaction testing
Acquisition comes through a $299 test per sale. What the platform delivers is a lender-compliant test with chain of custody: a certified sampler collects the sample, never the buyer or seller, and four states already require a test at sale and FHA and VA loans require one in defined circumstances (see Why Now). At that price, the panel is narrower than New Jersey's state-required panel (NJDEP-estimated $1,200โ$1,500) and assumes lab costs fall with volume; where a state or lender requires the broader panel, the transaction price rises to match. Cash sales and conventional loans carry no statutory mandate outside the four sale-rule states, though a lender may still require a test as a loan condition.
3. Treatment marketplace and verification
A failing result currently ends in a Google search for a filter salesman; the platform instead issues a treatment prescription tied to the specific exceedance, gets competing quotes from vetted local installers, and re-tests after installation to verify the fix worked. That verification is the part nobody sells today.
A whole-house filtration system runs $1,500 to $5,000 installed (HomeGuide 2026 average for well systems); PFAS-specific treatment varies more widely, and the referral fee is disclosed in dollars on every quote before the owner chooses, $150 to $750 on a typical install. Installers are ranked by verified pass rate, the share passing the verification re-test on the first attempt over the trailing 12 months, rather than fee size, and a percentage fee creates an incentive to recommend pricier systems. The platform writes the prescription from the exceedance, and the flat-fee verification lab must approve it before quotes go out, with a veto if the system is oversized for the exceedance. The referral is capped at $750 regardless of install price, a cap that binds only above about $5,000, so the percentage incentive persists across the typical range.
For verification, the lab is paid a flat fee by the platform regardless of the result, from a budget ring-fenced from referral revenue, so the party grading the work has no stake in the grade. Before launch, the referral-fee structure is subject to RESPA Section 8 and state anti-kickback review. That review has two questions. First, is a post-closing treatment-install referral even a referral of settlement-service business? Second, if so, does it fit a Section 8(c) exception or the affiliated-business-arrangement safe harbor? Disclosure alone does not cure a Section 8 violation.
4. Affordability and the sliding scale
Affordability is the problem with this layer: a $149 annual subscription plus a $1,500 to $5,000 treatment system prices out the low-income rural households most at risk. One question the business cannot answer is who should pay: PFAS is man-made industrial contamination, and the cost of finding and filtering it currently falls on the household that did nothing to put it there. There is no platform subsidy for treatment.
Households under 200 percent of the federal poverty level pay $99 a year instead of $149, a $50 discount funded from platform margin. The first panel costs $30 instead of $209. The $40 gap for the first 2,000 households is covered by the $80,000 pilot budget. After the pilot, the $30 first panel continues only where a state revolving fund or polluter settlement covers the $40 gap; otherwise it costs the list price.
Eligibility is by self-attestation at signup, with proof requested only if a funder requires it. The platform audits a random 5 percent sample of self-attested households each year. A failed audit ends the household's sliding-scale eligibility until proof is provided. Income-qualified subscriptions are capped at 2,500, the number assumed in the year-3 model. Beyond the platform, the funding sources are state revolving funds, polluter settlements, and free county testing, and the platform routes every owner to the free county option before selling them a panel.
5. Data layer for lenders, insurers, and counties
Once the platform holds year-by-year records for tens of thousands of wells, the record becomes infrastructure. Lenders query test status during underwriting instead of chasing PDFs, and in a lender-required transaction they see the pass-or-fail result as well. Counties get contamination maps built only from results owners opt in to sharing in anonymized form. Three rules govern what anyone else sees. First, what lenders and title companies buy, at $25 a report, is a status report covering test completed, date, and panel only, never the contaminant levels or a pass-or-fail result, and the report is sold only for a transaction the buyer-borrower has authorized.
Second, a pass-or-fail result against the lender's requirements is shared only with the seller-owner's explicit per-transaction consent, given separately from the status-report authorization, and only with that lender. Third, identifiable contaminant levels are never shared with lenders or insurers for any purpose, consent or not; a separate consent allows sharing them only with the owner's chosen installer or county health department. Pass-or-fail disclosure is effectively a condition of a lender-required transaction test: if the seller-owner will not authorize it, the buyer-borrower cannot close on that loan. Consent is the price of the loan.
County maps use only results owners opt in to sharing in anonymized form, with a minimum of five wells per cell and sparse cells suppressed, so no single well can be identified.
Renters and farmworkers get access to results for the water they drink, on different terms than an owner. A tenant who orders a test gets the dashboard in their own account and pays the $209 panel price. That test is the tenant's own record, never shared with the landlord without the tenant's consent. A tenant can also ask the owner to release the most recent result through the platform; where the owner declines, the tenant's own test is the record, and an existing-result right exists only under a law like New Jersey's PWTA. The platform assumes a tenant-initiated test needs no landlord permission, with the sampler entering as the tenant's guest, though wellhead access outside the dwelling and lease terms may limit that in practice.
The platform routes farmworkers through their county health department at no cost to the worker, with results in the worker's language and delivered to the worker only, never to the employer; where a county runs no program, the sliding scale applies. In New Jersey, the PWTA separately requires landlords to test every five years and give each tenant a copy of the results.
Deletion removes the platform's copy only. It cannot retract a status report or consented pass/fail already in a lender's file, identifiable levels already shared with an installer or county health department under separate consent, or anonymized aggregates already in a county map. A failed PFAS test in a lender's file can depress a property's value or kill a sale, so consent is the constraint the whole data layer is built around.
Revenue Model
| Revenue Stream | Amount | Year-3 revenue | Notes |
|---|---|---|---|
| Annual testing subscription | $149/year | $3.60M | 25,000 subscribers: 22,500 at $149/year and 2,500 income-qualified at $99/year. Kit, lab, dashboard, reminders. Lab cost ~$70 wholesale, gross margin ~53% at the $149 tier. |
| Transaction testing | $299 per sale; ~$509 blended | $4.07M | 8,000 sales. Certified sampler, chain of custody, lender-compliant report. Lab + sampler cost ~$120, higher for the broader New Jersey panel. Year-3 mix: the four sale-rule states plus one additional state contribute roughly equally, so about 20 percent of tests are New Jersey at ~$1,350, the midpoint of the NJDEP $1,200โ$1,500 range, and about 80 percent at $299, for a blended ~$509 per test. New Jersey is 20 percent of transaction volume but about 53 percent of transaction revenue. At a 40 percent New Jersey share, the transaction line would be about $5.8M. |
| Treatment referral | 10-15% of install | $375K | 1,500 verified installs at ~$2,500 average, $250 average referral, at 10%, the low end of the 10-15% range; at the 12.5% midpoint this would be $469K. Paid on verified completion, pass or fail; on a failed re-test the installer pays for the re-test and the fix. |
| B2B API and reports | $25/report, $12K/seat-year | $480K | 40 lender and title partners: 30 take seats at $12K, 10 report-only. ~4,800 status reports assumes 60% of the 8,000 transaction tests flow through partner channels, spread across all 40 partners at about 120 each a year. |
| Total | ~$8.5M | Sum of the four streams above ($8,528,600). |
Unit economics on a single subscriber: Acquisition through the transaction channel costs about $60, because the home sale already paid for the introduction, while direct acquisition through search costs $90 to $120, because those owners are acting on a scare or a sale. Blended across both channels, acquisition runs about $94 per subscriber: 6,000 of the 25,000 year-three subscribers arrived through transaction conversion over the first three years at $60, and 19,000, 76 percent, arrived direct at about $105, the midpoint of $90 to $120. At $149 a year against about $70 in lab and kit costs, and assuming a subscriber stays four years, lifetime gross profit is about $316. That is a 3.4x LTV to CAC ratio before any treatment referral, or about $296 and 3.1x with the 2,500 subsidized subscribers at $99 a year included. The 25 percent conversion rate is an assumption, not an observed rate: 8,000 transaction tests a year, the year-3 volume assumed flat across the first three years, at 25 percent yields 2,000 subscribers a year, so over three years transaction conversion supplies 6,000 of the 25,000 subscribers, retained under the four-year assumption, and direct acquisition supplies the other 19,000, about 6,300 a year.
Market Size
TAM: 23 million US households on private wells, at $149 a year for the annual subscription, is $3.4 billion a year in testing spend, before treatment referrals or B2B data revenue.
SAM: Two wedges are reachable without changing consumer behavior. First, the transaction wedge: about 690,000 well homes sell each year, worth $206 million a year at the transaction-panel price; second, the households that already test: about 2.3 million tested in the past year on the Iowa rate, and at $149 a year that is $343 million. Combined SAM is about $550 million a year. The two wedges are different purchases, so adding them does not double-count dollars, and a broader state-required panel would raise the transaction wedge where it applies; the 20 percent New Jersey share in the year-3 model is a launch-state concentration, not a national mix, and the SAM prices the transaction wedge at the national-average transaction price. The rest of the TAM requires convincing 20.7 million households to start testing.
SOM (year 3): 25,000 subscribers, 8,000 transaction tests, 1,500 verified treatment installs, and 40 B2B partners, for about $8.5 million in annual revenue, 1.6 percent of SAM and about a quarter of one percent of TAM. The constraint is sampler capacity and title-company partnerships, not demand: about 58,000 well homes change hands every month whether the platform is ready or not.
Why Now
The EPA drew a line that stops at the wellhead: private wells got nothing from the PFAS rule, and every news cycle about PFAS in public water sends well owners searching for a test, which is demand the platform does not have to create.
PFAS testing just got cheap: a 55-compound kit now runs about $85.
Four states wrote the template: New Jersey has required it since 2002, Oregon since 1989, Rhode Island before every sale or transfer, and Maryland since 2024, the most recent of the four; each state that adopts a sale rule creates a mandatory market overnight.
Those mandates create a second market: the record itself becomes a liability question, because if insurers and lenders start asking about well water in underwriting, a contaminated well is a property value and health liability problem at once. A lender that requires a year-by-year test record at origination makes the record a condition of the loan, which concentrates the market in whoever holds the records.
| Program | What it requires |
|---|---|
| New Jersey, Private Well Testing Act (since 2002) | Test is a condition of sale; closing only after buyer and seller review the results. Panel $1,200 to $1,500 (NJDEP estimate of the average price); a failed result does not itself prohibit the sale under the PWTA. |
| Oregon, ORS 448.271 | Seller tests arsenic, nitrate, coliform on acceptance; results to authority and buyer within 90 days of receipt. Non-compliance does not void sale. |
| Rhode Island, RIGL ยง5-20.8-12 | Buyer 10-day test period; void by written notice before the closing if results exceed limits, period omitted, or earlier results withheld. The parties may agree on a different test period, and may agree in writing on who pays; the void rights in ยง5-20.8-12(d) are statutory. |
| Maryland, Real Property ยง10-713 (since 2024) | Purchaser must ensure testing; waivable in writing. |
| FHA (HUD 4000.1) | Required in defined circumstances, including new construction, appraiser-flagged problems, known unsafe water, or sites near hazards. Report no more than 180 days old at disbursement; disinterested sampler. |
| VA | Water must meet the requirements of the health authority with jurisdiction, or EPA guidelines where the authority has none; results valid 90 days from certification unless authority says otherwise. Disinterested sampler. |
Startup Costs
| Category | Cost | Notes |
|---|---|---|
| Platform: ordering, dashboard, reminders, trend engine (9 months) | $350K | 2 backend, 1 frontend, 1 designer. |
| Lab partnerships and LIMS integration | $180K | Contracts with 3 certified labs for geographic coverage. |
| Chain-of-custody sampler network (5 launch states) | $150K | Recruiting, training, and scheduling certified samplers in the four sale-rule states plus one additional state to be named at launch. |
| State-by-state compliance mapping | $120K | Panel requirements, sampling rules, and reporting formats vary by state and county; one compliance lead for 12 months. |
| Title company and lender sales (year 1) | $180K | Two AEs at $90K loaded. |
| Legal: RESPA, PWTA confidentiality, lab liability | $60K | RESPA Section 8, PWTA confidentiality, state privacy, lab liability. |
| Pilot program (2,000 households, 3 states) | $80K | A $40 first-panel subsidy for 2,000 income-qualified households (lab cost $70, household pays $30). |
| Operating buffer (12 months) | $60K | Cloud hosting, kit fulfillment, support tooling. |
| Total | $1.18M |
The $1.18 million covers the nine-month build plus a year of operation, while the sampler network and title partnerships ramp, and what breaks first is sampler capacity in a second state, which is why the pilot is capped at 2,000 households.
Limitations
That 20.7-million-household untested figure is an extrapolation, not a measurement.
EPA's figures come from different vintages: 15 percent of the population and more than 23 million households, against a USGS 2020 estimate of about 17 percent of households with self-supplied water sources; an older 13 percent figure is population share as of 2015, not households.
Groundwater chemistry changes slowly, so the USGS figure is probably still roughly right for arsenic, manganese, and nitrate, but PFAS would only add exceedances on top of it.
One assumption behind the 4.8 million calculation is that untested wells are no more or less contaminated than tested ones, and the direction of the bias is unknown.
Comparison-site prices move over time, and the Cyclopure method is not yet as widely accepted by lenders as EPA Method 537.1. Treatment costs vary enormously by contaminant; $1,500 to $5,000 covers the common cases, not uranium or radium, and if lenders or states require New Jersey's broader $1,200 to $1,500 panel instead of the narrower one, transaction margins compress sharply.
All unit-economics inputs are model assumptions, not observed rates.
Real estate volume drives the transaction wedge, and 2024 was the weakest existing-home sales year since 1995 at 4.06 million, so if rates stay high and volume stays low, the 690,000 well-home sales figure falls with it, and the wedge narrows.
Strongest Counterargument
People do not test their water because they do not want to know. A well owner who has drunk from the same well for twenty years without getting sick has twenty years of evidence that the water is fine, and a lab report saying otherwise is an invitation to spend $3,000 on a filter for a problem they cannot see.
Testing rates are low not because testing is hard to buy but because the demand is not there. No reminder email fixes a preference. Preventive health is a graveyard of products that assumed people would pay for information about risks they prefer to ignore. A subscription that mails a kit once a year is a churn machine. The first year converts on a scare or a sale, the second year cancels on apathy, and the lifetime value math shrinks from four years to fourteen months, leaving lifetime gross profit just short of breakeven against the blended acquisition cost, though still 1.5x against the transaction channel alone.
That argument is strong, and the direct answer is that the subscription is not the wedge. The transaction is the wedge: a home sale forces the test regardless of preference, since a lender or a state law requires it, and the buyer at closing is the rare well owner who is actively thinking about the water. If the platform converts even a quarter of transaction customers to subscribers, the subscription business works, provided those subscribers stay past fourteen months. Retention has to be earned by catching a real change. A well's chemistry also changes, and the first time an annual test catches a nitrate spike from a new farm upstream, or a PFAS detection near a new industrial site, the value of the record becomes concrete.
Some wells will test clean for decades and those owners are rational to cancel, which means a subscription business will always carry customers whose correct decision is to stop paying. Expect that rather than fight it. The transaction and B2B revenue exists so the company does not need every subscriber to stay forever.
The Bottom Line
The bet is narrow and testable: if New Jersey transactions convert at a quarter and subscribers stay past fourteen months, the record business works, and if either fails, it is a lab-test reseller with a good dashboard. The company that turns a one-time test into a record, a reminder, and a verified fix, starting at the home sale where testing is already compelled, will own the dataset nobody else is building.
Build the record there, and the 20.7 million untested households can finally see their own water, with their test status visible to their lenders, and, in a lender-required transaction, the pass-or-fail result the loan effectively compels them to authorize.
A glass of water should not be a mystery you solve once a decade, if ever.
What You Can Do
If you drink from a private well: Check the free option first: many county health departments test well water for bacteria and nitrate at low or no cost, and Iowa's county grant program leaves about half its funding unused. If no free program covers you, order a comprehensive panel from a certified lab, one that includes bacteria, nitrate, lead, arsenic, and PFAS; Tap Score's Essential Well panel at $209 is a reasonable default. Test bacteria and nitrate every year after that, and keep every result in one folder with the date on it, because a single result tells you almost nothing and a trend tells you everything. If your result is bad and you cannot afford treatment, do not keep drinking it while you save up; switch to bottled water for drinking and cooking, and call your county health department before buying a system: some counties have grant money for treatment, and PFAS near an industrial site may qualify for polluter-funded cleanup. A $200 test that tells you to stop drinking the water is worth more than a $3,000 filter you cannot afford yet.
If you are buying a home with a well: Make the sale contingent on a certified test, and do not let the seller collect the sample. A $299 certified test with a disinterested sampler answers the FHA and VA water question before underwriting asks it, provided the results meet the lender's limits and the panel meets the lender's and the local authority's requirements. Time the test so the result is still within the VA 90-day validity window at closing. A clean year-by-year record is a selling point rather than a formality. Ask your lab whether results come with a trend record or just a PDF, and prefer the one that keeps the record.
If you are building this: Start with New Jersey transactions, not national subscriptions: the test is already mandatory, the panel is defined at $1,200 to $1,500 (NJDEP estimate). Build the sampler network and the lender-compliant report there, and follow the next state that adopts a sale rule, rather than launching the subscription nationally first: a reminder product with no forced moment behind it bleeds subscribers.
Related
๐ฐ PFAS Compliance Orchestration SaaS for Small Community Water Systems. The public-supply side of the same chemical: about 50,000 community water systems facing the same 4 parts-per-trillion limit, with no lab capacity of their own
๐ฐ Lead Service Line Inventory and Replacement Compliance SaaS for Small Water Utilities. The other invisible water risk is about 4 million lead service lines (EPA's revised November 2025 estimate, down from 9.2 million in 2024; NRDC disputes the revision, arguing it assumes unreported and unknown-material lines are lead-free and so undercounts), and the compliance layer being built around it
๐ฐ Radon Mitigation System Monitoring SaaS for Contractors and Property Managers. Another naturally occurring contaminant, another installed system nobody verifies after the truck leaves